scholarly journals A Comparative Study to Evaluate the Efficacy and Safety of Single Dose Intravenous Iron Carboxymaltose vs Multidose Iron Sucrose in Postpartum Cases of Severe Iron Deficiency Anemia

2015 ◽  
Vol 7 (1) ◽  
pp. 18-21
Author(s):  
Ruchika Garg ◽  
Renu Rajvanshi
Keyword(s):  
Adverse Reaction ◽  
Single Dose ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Efficacy And Safety ◽  
Group A ◽  
Group B

ABSTRACT Objective To evaluate the efficacy and safety of single dose intravenous iron carboxymaltose vs multidose iron sucrose in postpartum cases of severe iron deficiency anemia. Materials and methods One hundred cases with iron deficiency anemia in postpartum patient were selected from postpartum wards and assigned in two groups of 50 each. In group A, iron carboxymaltose injection administered by intravenous infusion upto a maximum single dose of 20 ml of iron carboxymaltose injection (1000 mg of iron). In group B Iron sucrose was given as 200 mg elemental iron (2 ampules of 5 ml) in 100 ml of 0.9% normal saline infusion over 15 minute alternate days up to 5 days. All the patients were monitored for rise in hemoglobin level at 2, 4, 8 and 12 weeks of iron therapy, adverse effect and rise in hematological parameter at 4 weeks. Results In group A, mean Hb level rise is 3.95 g/dl and in group B, it is 3.32 g/dl at 4 weeks of initial therapy. In group A, 100% cases achieved target Hb at 12 weeks after therapy while in group B 98% cases achieved target Hb at 12 weeks after therapy. In group A, 12% cases have grade 1 adverse reaction while in group B, 20% cases have adverse reaction. Conclusion Administration of intravenous iron has a good clinical result, with minimum adverse reactions. Thus, we can conclude that intravenous iron carboxymaltose therapy is safe, convenient, more effective and faster acting than intravenous iron sucrose for treatment of severe iron deficiency anemia in postpartum patient. How to cite this article Garg R, Singh S, Singh S, Rajvanshi R. A Comparative Study to Evaluate the Efficacy and Safety of Single Dose Intravenous Iron Carboxymaltose vs Multidose Iron Sucrose in Postpartum Cases of Severe Iron Deficiency Anemia. J South Asian Feder Obst Gynae 2015;7(1):18-21.

scholarly journals Comparison of ferric carboxymaltose versus Iron Sucrose for treatment of iron deficiency anemia in pregnancy.

2021 ◽  
Vol 28 (04) ◽  
pp. 481-484
Author(s):  
Hira Jamal ◽  
Humaira Zafar ◽  
Mubashra Naz ◽  
Umber Fatima ◽  
Anees Fatima
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Ferric Carboxymaltose ◽  
P Value ◽  
Iron Treatment ◽  
Group A ◽  
Group B

Objective: To compare the mean increase in hemoglobin level with ferric carboxymaltose injection and iron sucrose injection for the management of the pregnant females presenting with iron deficiency anemia. Study Design: Randomized Controlled Trial. Settings: Department of Obstetrics and Gynecology Madina Teaching Hospital affiliated with University medical and Dental College Faisalabad. Period: July 2019 to December 2019. Material & Method: A total number of 100 patients presented in OPD satisfying the selection criteria were enrolled in the study after permission from ethical committee. On enrollment, a detailed clinical history which include previous iron treatment including and chronic medical disorders was taken. Clinical examination was done. Investigations for anemia include hemoglobin, reticulocyte count, peripheral film and red cell indices, serum ferritin level and Hb electrophoresis if indicated. The patients were randomly divided in two groups. In group A, females were given ferric carboxymaltose and in group B, females were given iron sucrose. After calculating the total iron deficit, patients in group A were given intravenous FCM. Patients in group B were given IS. Follow up of the patient was done after 3 weeks of intravenous iron treatment. The baseline Hb and values after 3 weeks of intravenous iron treatment were compared between the FCM and IS groups and increase in Hb level calculated as mean and SD. Both groups were analyzed for rise in Hb level by using independent sample t test. P value < 0.05 was taken as significant. Results: A total 100 pregnant female were found eligible for study, and were randomized into two groups of 50 each. Mean increase in hemoglobin level with ferric carboxymaltose and iron sucrose was evaluated, it shows that baseline Hb was 8.84±0.68 in Group A and 8.78 ±0.76 in Group B, P value was 0.67, after treatment Hb was 12.02±0.89 in Group A and 10.92 ±0.99 in Group B. Mean increase was 3.18 ±0.60 in Group A and 2.14±0.81 in Group B. P value was 0.001. Conclusion: Ferric carboxymaltose significantly increase Hb level and restores the iron stores as compare to iron sucreose. FCM is safe and effective intravenous treatment for iron deficiency anemia in pregnancy. FCM has the advantages of single large dose administration and fewer hospital visit. FCM is most suitable drug for the treatment of patients with IDA who required quick replenishment of iron stores.

scholarly journals A study for efficacy and safety of ferric carboxymaltose versus iron sucrose in iron deficiency anemia among pregnant women in tertiary care hospital

2019 ◽  
Vol 8 (6) ◽  
pp. 2280
Author(s):  
Divyani Agrawal ◽  
Deepa Lokwani Masand
Keyword(s):  
Iron Deficiency ◽  
Adverse Events ◽  
Pregnant Women ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Ferric Carboxymaltose ◽  
Efficacy And Safety ◽  
Anemia During Pregnancy

Background: Anemia is one of the common manageable problem among the pregnant women worldwide, which contributes to maternal and perinatal mortality. This study aims to compare the efficacy and safety of intravenous ferric carboxymaltose with intravenous iron sucrose in treating anemia during pregnancy. Objective of this study was to compare safety and efficacy of intravenous ferric carboxymaltose with intravenous ferric sucrose in iron deficiency anemia during pregnancy.Methods: It’s an interventional prospective study conducted in Department of Obstetrics and Gynecology at NIMS, Jaipur, Rajasthan, India constituting of 100 pregnant women. Group 1- 50 pregnant women were treated with intravenous ferric carboxymaltose and Group 2: 50 pregnant women were treated with intravenous iron sucrose. Hemoglobin and serum ferritin levels were measured pre and post treatment with parenteral iron therapy. The efficacy of intravenous ferric carboxymaltose in comparison to intravenous iron sucrose was assessed. The evaluation of safety and tolerance with the parenteral therapy was also performed.Results: Anemia during pregnancy was more prevalent among the reproductive age group and in multiparous women. The mean rise in the hemoglobin level with ferric carboxymaltose was 2.92 gm/dl and with that of iron, sucrose was 1.08 gm/dl. The man rise in the serum ferritin levels with ferric carboxymaltose was 64.97ng/ml and with iron sucrose was 31.64 ng/ml. Ferric carboxymaltose was observed to be safer with no adverse events in comparison to the Iron sucrose which was related with adverse events among 03 pregnant women.Conclusions: Intravenous ferric carboxymaltose was more efficacious and safer in comparison to intravenous iron sucrose among pregnant women. Hence, ferric carboxymaltose is the drug of choice in treatment of iron deficiency anemia during pregnancy.

scholarly journals Comparison of efficacy and safety of intravenous iron sucrose and intramuscular iron sorbitol therapy in patients with anemia during pregnancy in a developing country

2017 ◽  
Vol 8 (5) ◽  
pp. 31-35
Author(s):  
Harsha Shailesh Gaikwad ◽  
Anu Sindhu ◽  
Nivedita Sarda
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Efficacy And Safety ◽  
Target Level ◽  
Medical Sciences ◽  
High Incidence ◽  
Anemia During Pregnancy

Background: Iron deficiency anemia due to poor nutritionis estimated to affect nearly two thirds ofall pregnant women in developing countriesparticularly in India. The responsible constellation of factors producing iron deficiency anemia generally precede the pregnancy, which includedeficient diet in iron content coupled with menstrual losses,generally a rapid succession of pregnancies and inadequate supplemental iron are a few to be blamed for a high incidence of anemia in such population.Aims and Objectives: To compare the efficacy and safety of iron sucrose versus iron sorbitol therapy in pregnant anemic patients.Material and Methods: Two-hundred antenatal women attending the out patient department having hemoglobin levels of 8 gm% or less were recruited in the study and were randomized into two groups for receiving intravenous and intramuscular iron therapy.Results and Conclusions: There was a significant improvement in the haematologicalparameters and no major side effects developed in the intravenous iron sucrose group.Though there was a significant improvement in the haematological parameters after intramuscular iron sorbitol therapy also butnone of the cases reached the target level of haemoglobinduring the observation period.Asian Journal of Medical Sciences Vol.8(5) 2017 31-35

scholarly journals To evaluate the efficacy and safety of intravenous bolus versus intravenous infusion of iron sucrose in pregnant women with severe iron deficiency anemia

2017 ◽  
Vol 6 (6) ◽  
pp. 2417
Author(s):  
Urvashi Verma ◽  
Saroj Singh ◽  
Shikha Singh ◽  
Anu Pathak ◽  
Poonam Yadav ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Gestational Age ◽  
Intravenous Infusion ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Intravenous Bolus ◽  
Medical College ◽  
Group A ◽  
Group B

Background: Objective of present study was to evaluate the efficacy and safety of intravenous bolus iron sucrose for iron deficiency anemia during pregnancy during second and third trimester women presenting at S.N. medical college, Agra.Methods: It was a prospective controlled trial and study was carried out in Department of Obstetrics and Gynecology, S.N. medical college, Agra in the year 2014-2016. 100Pregnant women with proved iron deficiency anemia having hemoglobin between 4-9gm/dl was included in this study. Total Iron deficit was calculated by standard formula. Target haemoglobin was 11gm/dl. Iron sucrose was administered by intravenous bolus and intravenous infusion techniques. Hemoglobin was repeated at 2 weeks, 4 weeks and 8 weeks after the last dose of intravenous iron sucroseResults: In Group A (bolus group n=50) 22 women had gestational age >24-28weeks and 20 women gestational age >18-24 weeks, with Mean gestational age of 24.36±3.78 weeks. In Group B (infusion group n=50) most of the patients 24 (48%) had gestational age >24-28 weeks, 18 (36%) had gestational age >18-24 weeks, with Mean gestational age of 24.94±3.51 weeks. Target hemoglobin was achieved in group A in all 50 (100%) cases and in group B in 49 (98%) cases. There were no allergic reactions.Conclusions: This study showed a significant improvement in the hemoglobin of the patients after receiving intravenous bolus and intravenous infusion of iron sucrose. Patients achieved the target hemoglobin of 11gm/dl. Both therapies are safe, effective and faster acting for the treatment of iron deficiency anaemia during pregnancy. The bolus push technique is more convenient to women and care provider, less time consuming as well as cost effective.

scholarly journals IRON DEFICIENCY ANEMIA

2007 ◽  
Vol 14 (02) ◽  
pp. 263-265
Author(s):  
RAHEELA FARHAT ◽  
DR. MAHNAAZ ROOHI
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Safety And Efficacy ◽  
Deficiency Anaemia ◽  
Group A ◽  
Group B

Objective: To evaluate the safety and efficacy of intra venous iron sucrose(venofer) as comparedto oral iron in treatment of iron deficiency anaemia during pregnancy. Study Design: Prospective study. Pregnantwomen with iron deficiency anaemia were selected from ante natal clinic. Patients were divided into two groups. GroupA: These patients were given oral iron. Group B: These patients were given intravenous sucrose. All patients wereevaluated for adverse effects, clinical and laboratory response >. Results: Intravenous group achieved a higher Hblevel in a shorter period. Group B showed no major side effects while (80%) of patients in Group A developedgastrointestinal symptoms. Conclusion: Intravenous iron sucrose is safe and effective in treatment of iron deficiencyanemia during pregnancy.

scholarly journals Efficacy and safety of intravenous iron sucrose therapy in a group of children with iron deficiency anemia

2015 ◽  
Vol 2 (1) ◽  
pp. 12 ◽  
Author(s):  
Sayyad Siddiqui ◽  
Deepali Jaybhaye ◽  
Anjali Kale ◽  
Jagannath Kakade ◽  
Madhuri Engade ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Efficacy And Safety

scholarly journals Efficacy and safety of intravenous iron sucrose treatment in children with iron deficiency anemia

2019 ◽  
Vol 6 (10) ◽  
pp. 278-283
Author(s):  
Elif Güler Kazancı ◽  
Muhammet Furkan Korkmaz ◽  
Betül Orhaner
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Efficacy And Safety ◽  
Oral Iron Therapy ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy

Objective:  The purpose of this study is to investigate the efficacy and safety of intravenous iron sucrose treatment in children with iron deficiency anemia who were unresponsive to or could not tolerate oral iron therapy. Material and Methods: Among patients determined to have iron deficiency anemia, and were intolerant or noncompliant with oral iron therapy, 92 patients who have received parenteral iron therapy between the ages of 6 months and 18 years have been investigated retrospectively. Age, gender, patient complaints at application,  dietary characteristics, accompanying diseases and treatment complications, and safety, tolerability, and adverse events have been assessed from the information obtained from patient files. Treatment efficiency was evaluated with hemoglobin (Hb), mean corpuscular volume (MCV) and ferritin results from the blood samples taken before treatment, at the second week of treatment and after two months. Results: Mean age of patients was 12.5 ± 4.7 (age interval 1-17 years), and 21% was male while 79% was female. 72% of our patients were adolescents. From an etiological aspect, 56% of our patients was determined to have an iron-poor diet, 29% had functional menorrhagia, and 15% had chronic gastrointestinal system pathologies. Mean Hb, MCV and ferritin levels before and after treatment were found as: 7.72 ± 1.21 g/dl and 11.44 g/dl ± 0.68 g/dl;  63.2 ± 7.12  fL and  76.6 ± 3.81  fL; 3.87 ± 2.52 nmol/L and 57.94 ± 17.19  nmol/L, respectively (p< 0.001). 94% of patients were determined to have at least 2 g/dL (mean value 3.71 [range 1.6-6.3]) increase in their Hb levels. Anaphylaxis was observed in a patient who had a history of allergy despite applying premedication. Conclusion: Parenteral iron therapy is an efficient and safe treatment among indicated patients.

scholarly journals Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery

2022 ◽  
Author(s):  
Michael Auerbach ◽  
Maureen M. Achebe ◽  
Lars L. Thomsen ◽  
Richard J. Derman
Keyword(s):  
Bariatric Surgery ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Efficacy And Safety ◽  
Open Label ◽  
Level Increase ◽  
Post Bariatric Surgery

Abstract Purpose Iron deficiency is common following bariatric surgery, and treatment with intravenous iron is often required. This post hoc analysis of data from two randomized, open-label, multicenter trials evaluated the efficacy and safety of ferric derisomaltose (FDI; formerly iron isomaltoside 1000) versus iron sucrose (IS) over 4 weeks in adults with iron deficiency anemia (IDA) resulting from prior bariatric surgery. Materials and methods Data were pooled for participants who received FDI or IS in the PROVIDE or FERWON-IDA trials for the treatment of IDA post bariatric surgery. Efficacy outcomes included changes in hemoglobin (Hb) and iron parameters; safety outcomes included the incidence of adverse drug reactions (ADRs), serious or severe hypersensitivity reactions (HSRs), and hypophosphatemia. Results The analysis included 159 patients. Mean (standard deviation) cumulative iron doses were 1199 (± 347) mg for FDI and 937 (± 209) mg for IS. Compared with IS, FDI resulted in a faster and more pronounced Hb response, and a higher proportion of responders (Hb level increase ≥ 2 g/dL from baseline) at all time points. The incidence of ADRs was similar with FDI and IS (15.1% and 18.2%, respectively), with no serious ADRs or serious or severe HSRs reported. The incidence of hypophosphatemia was low and similar in both treatment groups, with no cases of severe hypophosphatemia observed. Conclusions In patients with IDA resulting from bariatric surgery, FDI produced a faster and more pronounced Hb response than IS. Both FDI and IS were well tolerated. Graphical abstract

scholarly journals Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia

2011 ◽  
Vol 33 (6) ◽  
pp. 439-443 ◽  
Author(s):  
Rodolfo Delfini Cançado ◽  
Pedro Otavio Novis de Figueiredo ◽  
Maria Cristina Albe Olivato ◽  
Carlos Sérgio Chiattone
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document